A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with Relapsed and Refractory Multiple Myeloma (SWASTH) – RGCI, DELHI
An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti-CD38 antibody and have demonstrated disease progression on the last therapy – RGCI, DELHI